Hayato Tada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4003225/publications.pdf

Version: 2024-02-01

201674 168389 3,600 133 27 53 citations h-index g-index papers 133 133 133 5994 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Children with Severe Hypercholesterolemia Caused by a Pathogenic Mutation in <i>ABCG5</i> . Internal Medicine, 2023, 62, 251-259.	0.7	1
2	Machine learning-based risk model using 123I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure. Journal of Nuclear Cardiology, 2022, 29, 190-201.	2.1	25
3	Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. Heart and Vessels, 2022, 37, 327-336.	1.2	5
4	Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan. Journal of Atherosclerosis and Thrombosis, 2022, 29, 839-849.	2.0	19
5	Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, 29, 667-677.	2.0	7
6	Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. Journal of Atherosclerosis and Thrombosis, 2022, 29, 816-824.	2.0	20
7	Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design. Journal of Atherosclerosis and Thrombosis, 2022, 29, 953-969.	2.0	6
8	Human genetics and its impact on cardiovascular disease. Journal of Cardiology, 2022, 79, 233-239.	1.9	10
9	Acute Coronary Syndrome Developed in a 17-year-old Boy with Sitosterolemia Comorbid with Takayasu Arteritis: A Rare Case Report and Review of the Literature. Internal Medicine, 2022, 61, 1169-1177.	0.7	4
10	Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia. Atherosclerosis, 2022, 340, 28-34.	0.8	6
11	Individualized Treatment for Patients With Familial Hypercholesterolemia. Journal of Lipid and Atherosclerosis, 2022, 11, 39.	3.5	4
12	The Effect of Diet on Cardiovascular Disease, Heart Disease, and Blood Vessels. Nutrients, 2022, 14, 246.	4.1	6
13	A teenager boy with a novel variant of Sitosterolemia presented with pancytopenia. Clinica Chimica Acta, 2022, 529, 61-66.	1.1	3
14	Explainable Machine Learning for Atrial Fibrillation in the General Population Using a Generalized Additive Modelā€€â€• A Cross-Sectional Study ―. Circulation Reports, 2022, 4, 73-82.	1.0	1
15	Clinical and genetic features of sitosterolemia in Japan. Clinica Chimica Acta, 2022, 530, 39-44.	1.1	6
16	Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia. Frontiers in Genetics, 2022, 13, 872056.	2.3	8
17	Personalized medicine for cardiovascular diseases. Journal of Human Genetics, 2021, 66, 67-74.	2.3	23
18	Association of proteinuria with incident atrial fibrillation in the general Japanese population. Journal of Cardiology, 2021, 77, 100-105.	1.9	7

#	Article	IF	CITATIONS
19	Homozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 665-678.	2.0	55
20	Severe calcification of the Achilles' tendon. European Heart Journal, 2021, 42, 2217-2217.	2.2	2
21	Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents. Vascular Health and Risk Management, 2021, Volume 17, 59-67.	2.3	16
22	First-degree atrioventricular block is significantly associated with incident atrial fibrillation in the population predominantly including participants aged ≥ 60Âyears. Heart and Vessels, 2021, 36, 1401	- 1 : 2 09.	4
23	Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. Journal of Clinical Lipidology, 2021, 15, 358-365.	1.5	23
24	Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia. Frontiers in Cardiovascular Medicine, 2021, 8, 625852.	2.4	1
25	Challenges of Precision Medicine for Atherosclerotic Cardiovascular Disease Based on Human Genome Information. Journal of Atherosclerosis and Thrombosis, 2021, 28, 305-313.	2.0	8
26	Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia. Journal of Human Genetics, 2021, 66, 1079-1087.	2.3	9
27	Clinical Diagnostic Criteria of Familial Hypercholesterolemia ― A Comparison of the Japan Atherosclerosis Society and Dutch Lipid Clinic Network Criteria ―. Circulation Journal, 2021, 85, 891-897.	1.6	11
28	Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia. Circulation Journal, 2021, 85, 2073-2078.	1.6	24
29	Premature Acute Myocardial Infarction in a Young Patient With Sitosterolemia. CJC Open, 2021, 3, 1085-1088.	1.5	5
30	Diagnosis and Management of Sitosterolemia 2021. Journal of Atherosclerosis and Thrombosis, 2021, 28, 791-801.	2.0	50
31	Association between Cardiovascular Health and Incident Atrial Fibrillation in the General Japanese Population Aged ≥40 Years. Nutrients, 2021, 13, 3201.	4.1	6
32	Polygenic Risk Scores for AtheroscleroticÂCardiovascular Disease inÂthe Asia-PacificÂRegion. JACC Asia, 2021, 1, 294-302.	1.5	0
33	Effects of artificial intelligence-SsupporTed Automated NutRiTional Intervention on LDL cholesterol Control in Patients with Familial Hypercholesterolaemia (iSTART-FH): protocol for a randomised controlled trial. BMJ Open, 2021, 11, e053453.	1.9	1
34	Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. European Cardiology Review, 2021, 16, e54.	2.2	10
35	Clinical Impact of Carotid Plaque Score rather than Carotid Intima-Media Thickness on Recurrence of Atherosclerotic Cardiovascular Disease Events. Journal of Atherosclerosis and Thrombosis, 2020, 27, 38-46.	2.0	23
36	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. Journal of Atherosclerosis and Thrombosis, 2020, 27, 409-417.	2.0	29

#	Article	IF	Citations
37	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids in Health and Disease, 2020, 19, 3.	3.0	16
38	A case with familial hypercholesterolemia complicated with severe systemic atherosclerosis intensively treated for more than 30 years. Journal of Cardiology Cases, 2020, 22, 216-220.	0.5	3
39	Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency – Effects of pemafibrate treatment. Clinica Chimica Acta, 2020, 510, 216-219.	1.1	5
40	A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis. Practical Laboratory Medicine, 2020, 22, e00180.	1.3	3
41	Heterozygous (i>ABCG5 (li>Gene Deficiency and Risk of Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2020, 13, 417-423.	3.6	45
42	Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design. BMJ Open, 2020, 10, e038623.	1.9	3
43	Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community. Practical Laboratory Medicine, 2020, 22, e00181.	1.3	2
44	What is the mechanism of genetic contributions to the development of atherosclerosis?. Atherosclerosis, 2020, 307, 72-74.	0.8	4
45	Genomics of hypertriglyceridemia. Advances in Clinical Chemistry, 2020, 97, 141-169.	3.7	10
46	A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene. Internal Medicine, 2020, 59, 783-787.	0.7	8
47	Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy. Circulation Journal, 2020, 84, 509-515.	1.6	12
48	Impact of functional studies on exome sequence variant interpretation in early-onset cardiac conduction system diseases. Cardiovascular Research, 2020, 116, 2116-2130.	3.8	11
49	Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology. Journal of Atherosclerosis and Thrombosis, 2020, 27, 489-498.	2.0	14
50	Serum sitosterol level predicting ABCG5 or ABCG8 genetic mutations. Clinica Chimica Acta, 2020, 507, 11-16.	1.1	8
51	A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 346-351.e9.	1.5	20
52	Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous & lt;i>ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab. Internal Medicine, 2020, 59, 3033-3037.	0.7	9
53	Lipoprotein (a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients. Internal Medicine, 2020, 59, 1705-1710.	0.7	3
54	Functional analysis of KCNH2 gene mutations of type 2 long QT syndrome in larval zebrafish using microscopy and electrocardiography. Heart and Vessels, 2019, 34, 159-166.	1.2	14

#	Article	IF	CITATIONS
55	Genetic Variations, Triglycerides, and Atherosclerotic Disease. Journal of Atherosclerosis and Thrombosis, 2019, 26, 128-131.	2.0	11
56	Acute myocardial infarction in a patient positive for lupus anticoagulant: a case report. BMC Cardiovascular Disorders, 2019, 19, 167.	1.7	1
57	Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype. Circulation Journal, 2019, 83, 1917-1924.	1.6	55
58	A Japanese case of familial hypercholesterolemia with a novel mutation in the <i>LDLR</i> gene. Clinical Pediatric Endocrinology, 2019, 28, 19-22.	0.8	1
59	Rare Protein-Truncating Variants in <i>APOB</i> , Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002376.	3.6	57
60	Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis, 2019, 26, 583-591.	2.0	34
61	Monogenic, polygenic, and oligogenic familial hypercholesterolemia. Current Opinion in Lipidology, 2019, 30, 300-306.	2.7	18
62	Remnant lipoproteins and atherosclerotic cardiovascular disease. Clinica Chimica Acta, 2019, 490, 1-5.	1.1	23
63	Clinical whole exome sequencing in severe hypertriglyceridemia. Clinica Chimica Acta, 2019, 488, 31-39.	1.1	4
64	Encouragement of Super-aggressive LDL-lowering Therapies. Journal of Coronary Artery Disease, 2019, 25, 84-89.	0.3	0
65	Remnant-like particles and coronary artery disease in familial hypercholesterolemia. Clinica Chimica Acta, 2018, 482, 120-123.	1.1	15
66	Duration of cardiopulmonary resuscitation in patients without prehospital return of spontaneous circulation after out-of-hospital cardiac arrest: Results from a severity stratification analysis. Resuscitation, 2018, 124, 69-75.	3.0	17
67	Assessment of arterial stiffness in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 397-402.e2.	1.5	18
68	Acute myocardial infarction in a 25-year-old woman with sitosterolemia. Journal of Clinical Lipidology, 2018, 12, 246-249.	1.5	23
69	Molecular and functional characterization of familial chylomicronemia syndrome. Atherosclerosis, 2018, 269, 272-278.	0.8	16
70	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. Nutrients, 2018, 10, 1789.	4.1	32
71	Associations between questionnaires on lifestyle and atherosclerotic cardiovascular disease in a Japanese general population: A cross-sectional study. PLoS ONE, 2018, 13, e0208135.	2.5	10
72	Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol. BMJ Open, 2018, 8, e023636.	1.9	13

#	Article	IF	CITATIONS
73	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. Journal of Clinical Lipidology, 2018, 12, 1436-1444.	1.5	81
74	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. European Journal of Preventive Cardiology, 2018, 25, 1852-1860.	1.8	21
75	Oral Fat Tolerance Test for Sitosterolemia and Familial Hypercholesterolemia: A Study Protocol. Journal of Atherosclerosis and Thrombosis, 2018, 25, 741-746.	2.0	7
76	Effects of prehospital epinephrine administration on neurologically intact survival in bystander-witnessed out-of-hospital cardiac arrest patients with non-shockable rhythm depend on prehospital cardiopulmonary resuscitation duration required to hospital arrival. Heart and Vessels, 2018, 33, 1525-1533.	1.2	9
77	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2018, 25, 783-789.	2.0	90
78	First case of sitosterolemia caused by double heterozygous mutations in ABCG5 and ABCG8 genes. Journal of Clinical Lipidology, 2018, 12, 1164-1168.e4.	1.5	19
79	Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. Journal of Medical Case Reports, 2018, 12, 95.	0.8	17
80	Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 634-642.	2.0	15
81	Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing. Internal Medicine, 2018, 57, 1119-1122.	0.7	13
82	Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1188-1195.	2.0	8
83	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
84	Prehospital predictors of neurological outcomes in out-of-hospital cardiac arrest patients aged 95 years and older: A nationwide population-based observational study. Journal of Cardiology, 2017, 69, 340-344.	1.9	9
85	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	4.5	68
86	Renal glucosuria is not associated with atherosclerotic cardiovascular disease outcome in a general Japanese community. Atherosclerosis, 2017, 261, 111-116.	0.8	8
87	Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. Journal of Human Genetics, 2017, 62, 453-458.	2.3	15
88	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
89	Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. American Journal of Cardiology, 2017, 120, 1955-1960.	1.6	26
90	Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis, 2017, 265, 225-230.	0.8	20

#	Article	IF	CITATIONS
91	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. European Heart Journal, 2017, 38, 1573-1579.	2.2	132
92	Lipid Management in a Japanese Community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. Journal of Atherosclerosis and Thrombosis, 2017, 24, 338-345.	2.0	24
93	Lipoprotein Apheresis for Sitosterolemia. Annals of Internal Medicine, 2017, 167, 896.	3.9	13
94	Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2017, 24, 452-461.	2.0	21
95	Age-Specific Differences in the Duration of Prehospital Cardiopulmonary Resuscitation Administered by Emergency Medical Service Providers Necessary to Achieve Favorable Neurological Outcome After Out-of-Hospital Cardiac Arrest. Circulation Journal, 2017, 81, 652-659.	1.6	8
96	Huge right ventricular mass lesion associated with genital malignant tumor: a case report. Journal of Medical Case Reports, 2017, 11, 282.	0.8	0
97	Do We Expect Any Pleiotropic Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition for Reducing Cardiovascular Events Beyond Low-Density Lipoprotein Cholesterol Reduction?. Circulation Journal, 2017, 81, 1098-1099.	1.6	1
98	Significance of Genetic Diagnosis of Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 554-556.	2.0	0
99	Common and Rare Variant Association Study for Plasma Lipids and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 241-256.	2.0	15
100	A Rare Coincidence of Sitosterolemia and Familial Mediterranean Fever Identified by Whole Exome Sequencing. Journal of Atherosclerosis and Thrombosis, 2016, 23, 884-890.	2.0	20
101	Impact of Updated Diagnostic Criteria forÂLong QT Syndrome on Clinical Detection ofÂDiseased Patients. JACC: Clinical Electrophysiology, 2016, 2, 279-287.	3.2	9
102	Age-specific differences in prognostic significance of rhythm conversion from initial non-shockable to shockable rhythm and subsequent shock delivery in out-of-hospital cardiac arrest. Resuscitation, 2016, 108, 61-67.	3.0	19
103	Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (<i>PCSK9</i>) Gain-of-Function Mutations. Circulation Journal, 2016, 80, 512-518.	1.6	67
104	Prevalence, clinical features, and prognosis of patients with extremely low high-density lipoprotein cholesterol. Journal of Clinical Lipidology, 2016, 10, 1311-1317.	1.5	9
105	Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease, 2016, 15, 66.	3.0	7
106	Usefulness of Electrocardiographic Voltage to Determine Myocardial Fibrosis in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 443-449.	1.6	22
107	Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. European Heart Journal, 2016, 37, 561-567.	2.2	226
108	A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing. Clinica Chimica Acta, 2016, 453, 194-196.	1.1	9

#	Article	IF	CITATIONS
109	Whole exome sequencing combined with integrated variant annotation prediction identifies a causative myosin essential light chain variant in hypertrophic cardiomyopathy. Journal of Cardiology, 2016, 67, 133-139.	1.9	14
110	Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method. Practical Laboratory Medicine, 2015, 1, 22-27.	1.3	5
111	Whole Exome Sequencing in Monogenic Dyslipidemias. Journal of Atherosclerosis and Thrombosis, 2015, 22, 881-885.	2.0	3
112	Autosomal Recessive Hypercholesterolemia: A Mild Phenotype of Familial Hypercholesterolemia: Insight from the Kinetic Study using Stable Isotope and Animal Studies. Journal of Atherosclerosis and Thrombosis, 2015, 22, 1-9.	2.0	22
113	Infantile Cases of Sitosterolaemia with Novel Mutations in the ABCG5 Gene: Extreme Hypercholesterolaemia is Exacerbated by Breastfeeding. JIMD Reports, 2015, 21, 115-122.	1.5	45
114	Exome Sequencing in Suspected Monogenic Dyslipidemias. Circulation: Cardiovascular Genetics, 2015, 8, 343-350.	5.1	45
115	Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography. American Journal of Cardiology, 2015, 115, 724-729.	1.6	60
116	Clinical characteristics of Japanese patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2015, 9, 519-524.	1.5	29
117	Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1095-1104.	4.8	44
118	Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene. Atherosclerosis, 2015, 240, 324-329.	0.8	16
119	Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia. JIMD Reports, 2015, 22, 85-94.	1.5	12
120	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	3.4	1
121	Multiple Associated Variants Increase the Heritability Explained for Plasma Lipids and Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2014, 7, 583-587.	5.1	29
122	Twelve–Single Nucleotide Polymorphism Genetic Risk Score Identifies Individuals at Increased Risk for Future Atrial Fibrillation and Stroke. Stroke, 2014, 45, 2856-2862.	2.0	95
123	Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis, 2014, 236, 54-61.	0.8	78
124	Altered Metabolism of Low-Density Lipoprotein and Very-Low-Density Lipoprotein Remnant in Autosomal Recessive Hypercholesterolemia. Circulation: Cardiovascular Genetics, 2012, 5, 35-41.	5.1	40
125	Novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic subjects. Clinica Chimica Acta, 2012, 413, 537-543.	1.1	14
126	Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. American Journal of Cardiology, 2012, 109, 364-369.	1.6	35

#	Article	IF	CITATION
127	Postâ€prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. European Journal of Clinical Investigation, 2012, 42, 1094-1099.	3.4	16
128	Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study. Clinica Chimica Acta, 2011, 412, 1068-1075.	1.1	11
129	Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011, 214, 404-407.	0.8	99
130	A novel type of familial hypercholesterolemia: Double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis, 2011, 219, 663-666.	0.8	43
131	The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis, 2010, 210, 166-172.	0.8	62
132	A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: Application of the CD3/CD28 assay in lymphocytes. Clinica Chimica Acta, 2009, 400, 42-47.	1.1	21
133	Huge Apertures in the Aortic Valve Due to Libman-Sachs Endocarditis. Internal Medicine, 2009, 48, 859-859.	0.7	1